tradingkey.logo

Dexcom Inc

DXCM
View Detailed Chart
66.060USD
+0.150+0.23%
Close 12/19, 16:00ETQuotes delayed by 15 min
25.76BMarket Cap
35.86P/E TTM

Dexcom Inc

66.060
+0.150+0.23%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.23%

5 Days

-1.34%

1 Month

+10.60%

6 Months

-18.45%

Year to Date

-15.06%

1 Year

-12.87%

View Detailed Chart

TradingKey Stock Score of Dexcom Inc

Currency: USD Updated: 2025-12-19

Key Insights

Dexcom Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 28/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 86.34.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dexcom Inc's Score

Industry at a Glance

Industry Ranking
28 / 208
Overall Ranking
97 / 4582
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 31 analysts
Buy
Current Rating
86.336
Target Price
+31.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Dexcom Inc Highlights

StrengthsRisks
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 38.60% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.03B.
Undervalued
The company’s latest PE is 35.86, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 388.08M shares, increasing 0.05% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 103.84K shares of this stock.

Dexcom Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Dexcom Inc Info

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Ticker SymbolDXCM
CompanyDexcom Inc
CEOMr. Jacob Steven (Jake) Leach
Websitehttps://www.dexcom.com/

FAQs

What is the current price of Dexcom Inc (DXCM)?

The current price of Dexcom Inc (DXCM) is 66.060.

What is the symbol of Dexcom Inc?

The ticker symbol of Dexcom Inc is DXCM.

What is the 52-week high of Dexcom Inc?

The 52-week high of Dexcom Inc is 93.250.

What is the 52-week low of Dexcom Inc?

The 52-week low of Dexcom Inc is 54.110.

What is the market capitalization of Dexcom Inc?

The market capitalization of Dexcom Inc is 25.76B.

What is the net income of Dexcom Inc?

The net income of Dexcom Inc is 576.20M.

Is Dexcom Inc (DXCM) currently rated as Buy, Hold, or Sell?

According to analysts, Dexcom Inc (DXCM) has an overall rating of Buy, with a price target of 86.336.

What is the Earnings Per Share (EPS TTM) of Dexcom Inc (DXCM)?

The Earnings Per Share (EPS TTM) of Dexcom Inc (DXCM) is 1.842.
KeyAI